HUP0202703A2 - Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0202703A2
HUP0202703A2 HU0202703A HUP0202703A HUP0202703A2 HU P0202703 A2 HUP0202703 A2 HU P0202703A2 HU 0202703 A HU0202703 A HU 0202703A HU P0202703 A HUP0202703 A HU P0202703A HU P0202703 A2 HUP0202703 A2 HU P0202703A2
Authority
HU
Hungary
Prior art keywords
adp
poly
polymerases
ribose
alkyl
Prior art date
Application number
HU0202703A
Other languages
English (en)
Inventor
Walter Brian Eastman
Robert Arnold Kumpf
Joseph Timothy Marakovits
Donald James Skalitzky
Jayashree Girish Tikhe
Stephen Evan Webber
Original Assignee
Agouron Pharmaceuticals, Inc.
Cancer Research Campaign Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc., Cancer Research Campaign Technology Ltd. filed Critical Agouron Pharmaceuticals, Inc.
Publication of HUP0202703A2 publication Critical patent/HUP0202703A2/hu
Publication of HUP0202703A3 publication Critical patent/HUP0202703A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát képezik az (I) általános képletű vegyületek - ahola szubsztituensek jelentése az alábbiakban megadott - poli(ADP-ribozil) transzferáz inhibitorok. Az ilyen vegyületek gyógyszerekhatóanyagaként rákok kezelésére és gutaütés, fejsérülés vagyneurodegeneratív betegség hatásainak enyhítésére alkalmazhatók. Aszubsztituensek jelentése: X jelentése O vagy S; Y jelentése N vagyCR3; R1 jelentése cianocsoport; szubsztituált alkil- vagy adottesetben szubsztituált alkenil-, alkinil-, cikloalkil-,heerocikloalkil-, aril- vagy heteroarilcsoport; R2 jelentése H vagyalkilcsoport; R4 jelentése H, halogénatom vagy alkilcsoport; R5, R6,R7 és R8 jelentése, egymástól függetlenül H; adott esetbenszubsztituált alkil-, alkenil-, alkinil-, cikloalkil-,heterocikloalkil-, aril- vagy heteroaril-csoport Ó
HU0202703A 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases and pharmaceutical compositions containing them and their use HUP0202703A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (2)

Publication Number Publication Date
HUP0202703A2 true HUP0202703A2 (hu) 2002-12-28
HUP0202703A3 HUP0202703A3 (en) 2004-12-28

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202703A HUP0202703A3 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases and pharmaceutical compositions containing them and their use

Country Status (48)

Country Link
US (1) US6548494B1 (hu)
EP (1) EP1208104B1 (hu)
JP (1) JP4272375B2 (hu)
KR (1) KR20020038742A (hu)
CN (1) CN1384835A (hu)
AP (1) AP1553A (hu)
AR (1) AR035162A1 (hu)
AT (1) ATE287406T1 (hu)
AU (1) AU781826B2 (hu)
BG (1) BG106562A (hu)
BR (1) BR0015051A (hu)
CA (1) CA2382404C (hu)
CO (1) CO5200769A1 (hu)
CR (1) CR6577A (hu)
CZ (1) CZ2002613A3 (hu)
DE (1) DE60017575T2 (hu)
DK (1) DK1208104T3 (hu)
DO (1) DOP2000000069A (hu)
DZ (1) DZ3216A1 (hu)
EA (1) EA200200306A1 (hu)
EC (1) ECSP003637A (hu)
EE (1) EE200200100A (hu)
ES (1) ES2234657T3 (hu)
GE (1) GEP20043268B (hu)
GT (1) GT200000145A (hu)
HK (1) HK1045509B (hu)
HR (1) HRP20020271A2 (hu)
HU (1) HUP0202703A3 (hu)
IL (1) IL147863A0 (hu)
IS (1) IS6289A (hu)
MA (1) MA25876A1 (hu)
MX (1) MXPA02002138A (hu)
MY (1) MY135910A (hu)
NO (1) NO322475B1 (hu)
NZ (1) NZ516793A (hu)
OA (1) OA12016A (hu)
PA (1) PA8501801A1 (hu)
PE (1) PE20010538A1 (hu)
PL (1) PL354242A1 (hu)
PT (1) PT1208104E (hu)
SI (1) SI1208104T1 (hu)
SK (1) SK2592002A3 (hu)
SV (1) SV2003000162A (hu)
UA (1) UA73144C2 (hu)
UY (1) UY26323A1 (hu)
WO (1) WO2001016136A2 (hu)
YU (1) YU15102A (hu)
ZA (1) ZA200200830B (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143349A0 (en) * 1999-09-28 2002-04-21 Basf Ag Azepinoindole derivatives, the production and use thereof
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
AU2003236686A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors
EP1947102A1 (en) 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
DK1660095T3 (da) * 2003-07-25 2010-05-25 Cancer Rec Tech Ltd Tricykliske PARP-inhibitorer
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
RU2413515C2 (ru) 2003-12-01 2011-03-10 Кудос Фармасьютикалс Лимитед Ингибиторы репарации повреждения днк для лечения рака
SI1794163T1 (sl) * 2004-09-22 2010-04-30 Pfizer Postopek priprave inhibitorjev poli(ADP-riboza) polimeraz
MX2007008771A (es) * 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
JP2008543841A (ja) 2005-06-14 2008-12-04 シェーリング コーポレイション 大環状複素環式アスパルチルプロテアーゼインヒビター
JPWO2006137510A1 (ja) * 2005-06-24 2009-01-22 小野薬品工業株式会社 脳血管障害時における出血低減剤
KR20080035630A (ko) * 2005-07-18 2008-04-23 바이파 사이언스 인코포레이티드 암의 치료
MX2008001152A (es) * 2005-08-05 2008-04-02 Astrazeneca Ab Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
EP2061479A4 (en) * 2006-09-05 2010-08-04 Bipar Sciences Inc FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
BRPI0812740A2 (pt) 2007-06-05 2016-07-19 Nsab Af Neurosearch Sweden Ab composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
JP2011503071A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
WO2009073869A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2892344A1 (de) * 2012-09-05 2015-07-15 Bayer CropScience AG Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
CN106458935B (zh) 2014-01-05 2019-05-28 华盛顿大学 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
MX2020007060A (es) 2018-01-05 2020-11-11 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
JP2021530442A (ja) * 2018-06-28 2021-11-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co., Ltd. 縮合三環系複素環化合物およびその治療上の使用
EP3842437B1 (en) * 2018-08-24 2024-04-10 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
EP3873896A4 (en) * 2018-12-14 2022-08-31 Jiangsu Hengrui Medicine Co., Ltd. TRICYCLIC COMPOUNDS AS STING AGONISTS AND METHODS OF MANUFACTURE AND MEDICAL USES THEREOF
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230002487A (ko) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
US20240093250A1 (en) 2021-01-08 2024-03-21 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
MX2023011793A (es) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (hu) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
AU714873B2 (en) * 1995-08-02 2000-01-13 Newcastle University Ventures Limited Benzimidazole compounds
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
WO1998051308A1 (en) 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
AU9297998A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity

Also Published As

Publication number Publication date
BR0015051A (pt) 2002-06-25
CA2382404A1 (en) 2001-03-08
ES2234657T3 (es) 2005-07-01
YU15102A (sh) 2004-12-31
CO5200769A1 (es) 2002-09-27
ECSP003637A (es) 2002-03-25
DK1208104T3 (da) 2005-05-02
MXPA02002138A (es) 2003-08-20
EP1208104A2 (en) 2002-05-29
AP1553A (en) 2006-01-18
CA2382404C (en) 2009-03-24
EA200200306A1 (ru) 2002-08-29
DE60017575D1 (de) 2005-02-24
PA8501801A1 (es) 2002-08-26
SK2592002A3 (en) 2002-10-08
ZA200200830B (en) 2003-03-26
HUP0202703A3 (en) 2004-12-28
BG106562A (bg) 2003-03-31
JP2003513015A (ja) 2003-04-08
PL354242A1 (en) 2003-12-29
WO2001016136A3 (en) 2001-06-21
GEP20043268B (en) 2004-06-25
HRP20020271A2 (en) 2005-12-31
DOP2000000069A (es) 2002-08-30
AU7338900A (en) 2001-03-26
CZ2002613A3 (cs) 2002-08-14
IS6289A (is) 2002-02-27
UA73144C2 (en) 2005-06-15
EE200200100A (et) 2003-06-16
DE60017575T2 (de) 2005-06-09
HK1045509B (zh) 2005-04-29
NO322475B1 (no) 2006-10-09
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
DZ3216A1 (fr) 2001-03-08
WO2001016136B1 (en) 2001-11-15
KR20020038742A (ko) 2002-05-23
UY26323A1 (es) 2001-04-30
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
CN1384835A (zh) 2002-12-11
AR035162A1 (es) 2004-05-05
AU781826B2 (en) 2005-06-16
PT1208104E (pt) 2005-04-29
NO20020421L (no) 2002-04-25
MY135910A (en) 2008-07-31
HK1045509A1 (en) 2002-11-29
SI1208104T1 (en) 2005-06-30
GT200000145A (es) 2002-02-21
NO20020421D0 (no) 2002-01-28
CR6577A (es) 2003-12-05
JP4272375B2 (ja) 2009-06-03
EP1208104B1 (en) 2005-01-19
ATE287406T1 (de) 2005-02-15
PE20010538A1 (es) 2001-05-22
IL147863A0 (en) 2002-08-14
MA25876A1 (fr) 2003-10-01
NZ516793A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
HUP0202703A2 (hu) Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0204141A2 (hu) Pirido[2,3-d]pirimidin-2,7-diamin típusú kináz-inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ATE361287T1 (de) Neue indol-2-on derivate
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
SE0102438D0 (sv) New compounds
SE9902987D0 (sv) Novel compounds
BR0108679A (pt) Novos compostos
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
SE0202133D0 (sv) Novel compounds
UY27592A1 (es) Nuevo uso
HUP0300527A2 (hu) Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása
PA8495101A1 (es) Derivados de 13-metileritromicina
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
SE0302139D0 (sv) Novel compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
HUP0401883A2 (hu) Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények
ATE401080T1 (de) (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
SE0300456D0 (sv) Novel compounds
NO930143D0 (no) Piperidinforbindelser, deres fremstilling og bruk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees